BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS

Beta Bionics (NASDAQ: BBNX) faces a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant shareholder losses during the class period of July 30, 2025 to February 24, 2026.